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INTRODUCTION
CD36 is a heavily glycosylated, single chain, integral plasma membrane protein that belongs to an evolutionarily conserved family of proteins that serve as scavenger and lipid receptors (1, 2) . It is expressed on the surface of adipocytes, microvascular endothelial cells, macrophages, platelets, and specialized epithelial cells (1, 2) . CD36 functions in vivo in scavenger recognition of oxidized lipoproteins and senescent or apoptotic cells, fatty acid transport, cell-matrix interactions, and antiangiogenic actions (3) (4) (5) . Its deficiency in humans has been correlated with alterations in myocardial fatty acid uptake, hypertrophic cardiac myopathy and insulin resistance (6) (7) (8) . Recent studies have focused attention on CD36 as a participant in the atherosclerotic process because of its ability to recognize oxidized forms of LDL (oxLDL) (3, 4, (9) (10) (11) . CD36 mediates lipid accumulation and macrophage foam cell formation in vitro and in vivo (3, 12, 13) . It is heavily expressed in lipid rich atheroma and CD36 knockout mice demonstrate a dramatic decrease in lesion progression (9) . In addition, uptake of oxLDL through CD36 plays a role in differentiation of monocytes and in the induction of nuclear receptors such as the peroxisome proliferator-activated receptor γ (PPARγ), a receptor that participates in lipid and carbohydrate metabolism (12, (14) (15) (16) .
We recently described a pathway for oxidative modification of LDL by the myeloperoxidase (MPO)-H 2 O 2 -NO 2 -system of monocytes (17) . LDL modified by MPO-generated reactive nitrogen species (NO 2 -LDL) is avidly taken up and degraded by macrophages in vitro, leading to cholesterol deposition and foam cell formation. The macrophage scavenger receptor CD36 is responsible for M2:03318 Identification of oxidized lipid ligands for CD36 pathophysiological concentrations of nitrite and in the presence of serum constituents, in contrast to LDL oxidation by free transition metal ions (e.g. Cu 2+ ) (10) . Moreover, studies examining peroxidation of endogenous plasma lipids by activated leukocytes isolated from normal and MPO-deficient subjects strongly supports a role for the MPO-H 2 O 2 system of human leukocytes as a physiological mechanism for initiating lipid peroxidation in vivo (25). Finally, a recent clinical study identified MPO levels in blood and leukocytes as strong independent predictors of coronary artery disease in angiographically defined subjects (26) .
Although the scavenger receptor functions of CD36 are well documented, the exact molecular structure(s) of the ligand(s) recognized by CD36 remain unknown. Oxidized lipids were first suggested to participate in recognition of oxLDL by mouse peritoneal macrophages (MPM) based on studies using liposomes generated from lipid extracts of LDL that was extensively oxidized by Cu 2+ (Cu 2+ -oxLDL) (27) . A role for CD36 as the receptor responsible for recognition of oxidized lipids extracted from Cu 2+ -oxLDL was subsequently shown (10, 11) . Oxidized phospholipids covalently linked to apolipoprotein B-100 (apoB) in extensively oxidized LDL (e.g. Cu 2+ -oxLDL) have also been suggested to serve as ligands for CD36 based upon indirect competition studies using a monoclonal antibody to oxidized PAPC-protein adducts and either reconstituted apoB from Cu 2+ -oxLDL or adducts of BSA with the aldehydic phospholipid 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine (OV-PC), an oxidation product of PAPC (11, 28, 29) . We have shown that the lipid portion of LDL and PAPC vesicles that are mildly oxidized by the MPO-H 2 O 2 -NO 2 -system serve as ligands for CD36 using stable transfected cells and mouse peritoneal macrophages (MPM) from wild type vs. CD36 knockout mice (10) . Conversion of LDL into a ligand for CD36 is a very early event during LDL oxidation in this system, occurring before substantial modification of apoB, as monitored by loss of free lysine residues and alteration in relative electrophoretic mobility (10) .
While studies thus far clearly support the notion that oxidized phospholipids play a major role in the binding of oxLDL forms (including NO 2 -LDL) to CD36, particularly early in the oxidation process, the precise nature of the lipid ligand or ligands within the lipid phase of oxLDL species have not yet been identified. We now report the first systematic study aimed at directly identifying the structures of specific oxidized phospholipids that serve as high affinity ligands for the scavenger receptor CD36.
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EXPERIMENTAL PROCEDURES
Materials
Tissue culture media and additives were purchased from Life Technologies (Gaithersburg, MD). 20 weeks of age) were purchased from the Trudeau Institute (Saranac Lake, NY). 1-Hexadecanoyl-2-eicosatetra-5',8',11',14'-enoyl-sn-glycero-3-phosphocholine (PAPC), 1-hexadecanoyl-2-octadec-9'-enoyl-sn-glycero-3-phosphocholine (POPC) and 1-hexadecanoyl-2-octadec-9',12'-dienoyl-sn-glycero-3-phosphocholine (PLPC), phosphatidyl serine (PS) and 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC) were purchased from Avanti Polar Lipids (Alabaster, AL). Anti-CD36 monoclonal antibody, FA6-152, was purchased from Immunotech (Westbrook, ME). All other reagents were obtained from Sigma Chemical Co. (St. Louis, MO) unless otherwise specified.
Na
Methods
General procedures. Human myeloperoxidase (donor: hydrogen peroxide, oxidoreductase, EC 1.11.1.7) and LDL were isolated and quantified as described (17) . All buffers were treated with Chelex-100 resin (Bio-Rad, Hercules, CA) and supplemented with diethylenetriaminepentaacetic acid (DTPA)
to remove trace levels of transition metal ions that might catalyze LDL oxidation during incubations.
LDL was labeled with Na[ 125 I] to a specific activity between 100 and 250 dpm/ng protein, as described (30) . Extraction of cellular lipids and thin-layer chromatography separation of radiolabeled cholesterol esters were performed as described (17) . Incorporation of [ 14 C]oleate into cholesteryl esters by cells following incubation with the indicated lipoproteins (50 µg/ml), were determined as described (17) .
M2:03318 Identification of oxidized lipid ligands for CD36 6 octendioic acid esters of 2-lysoPC (KDdiA-PC and KOdiA-PC, respectively) were performed as described elsewhere (32) . Saturated aldehydic phospholipids, the 5-oxovaleric acid and 9-oxononanoic acid esters of 2-lysoPC (OV-PC and ON-PC, respectively) were synthesized from stable phospholipid precursors containing a dimethylacetal-protected carbonyl that was deprotected in the presence of catalytic amounts of acidic ion-exchange resin Amberlyst-15 (29) . Their carboxylic analogs, the glutaric and nonanedioic monoesters of 2-lysoPC (G-PC, ND-PC, respectively), were prepared by coupling 2-lyso-PC with the corresponding acid anhydride (29, 32) . Purification was achieved by flash silica column chromatography or HPLC, as described elsewhere (29, 32) . The structures of all synthetic lipids were confirmed by multinuclear NMR and high resolution mass spectrometry prior to use (29, 31, 32) .
Synthetic lipids were routinely analyzed by HPLC with on-line electrospray ionization tandem mass spectrometry. If lipids were found to be less than 98% pure, they were re-isolated prior to use.
Vesicle preparation and modification. Stock solutions (2 mg/ml) of small unilamellar vesicles comprised of PLPC, POPC or PAPC with varying mol % of specific oxidized phospholipids were prepared in argon-sparged sodium phosphate buffer by extrusion (ten times) through a 0.1 µm polycarbonate filter using an Avanti Mini-Extruder Set (Avanti Polar Lipids, Inc., Alabaster, AL) at 37°C. For direct binding experiments, [ 3 H]DPPC (25 µCi/mg of phospholipids) or 1 mol % of the fluorescent dye DiI was added to phospholipids. CD36 ligands were isolated from PAPC or PLPC vesicles (0.2 mg lipid/ml) following incubation with MPO (30 nM), an H 2 O 2 -generating system (constant flux of 0.80 µM/min) comprised of glucose (100 µM) and glucose oxidase (100 ng/ml), and NaNO 2 (0.5 mM) at 37°C for 20 h. Reactions were stopped by the addition of BHT (50 µM) and catalase (300 nM) and stored under argon atmosphere at -80°C. with solvent A from 0-7 min; increasing to 88% solvent B from 7-10 min; increasing to 91% solvent B from 10-34 min; and then increasing to 94% solvent B from 34-52 min. The column effluent was split such that 45 µl/min was introduced to the mass spectrometer and 755 µl/min was collected and analyzed for biological activity. In some cases, biological activity was also determined using the same gradient following injection of authentic standards. Mass spectrometric analyses were performed on- conditions. Lipids derivatizations with NaBH 4 , NaCNBH 3 and dinitrophenylhydrazone were performed as described (37) .
Statistics. Data represent the mean ± S.D. of the indicated number of samples. Statistical analyses were made using a paired Student's t test. For all hypotheses, the significance level was 0.05. 
RESULTS
Identification
Identification of CD36 ligands in peaks I, II and III derived from NO 2 -PAPC and NO 2 -PLPC.
Each fraction possessing CD36 binding activity was further subjected to sequential reverse phase HPLC separation with on-line electrospray ionization tandem mass-spectrometry (LC/ESI/MS/MS) using a distinct solvent system and elution gradient from that initially employed. The column eluent was split (45µl/min to the mass detector and the remainder to a fraction collector), and the capacity of lipids within the fractions to inhibit binding of [ 125 I]NO 2 -LDL to CD36-transfected 293 cells was determined.
Molecular structures for the major biologically active constituents in Peaks I, II, and III derived from lipids in NO 2 -PAPC and NO 2 -PLPC vesicles were determined by a combination of tandem mass spectrometry (in both positive and negative ion modes) of active fractions, and unambiguous total syntheses by methods either recently described (31) or that will be reported elsewhere (32) . The identities of the isolated oxidation products and synthetic standards were confirmed by derivatization with multiple agents (NaBH 4 , NaBD 4 , and NaCNBH 3 for reducible groups; methyl hydroxyl amine and dinitrophenyhydrazone for reactive carbonyl moieties; pentaflourobenzyl bromide for carboxyl groups), and subsequent tandem MS analysis in both positive ion and negative ion modes (data not shown).
The structures of the oxidized PC species possessing CD36 binding activity (oxPC CD36 ) are shown in Fig. 1c . Of note, the structures identified for Peaks I, II and III isolated from oxidized PLPC species were the structural analogs of the respective lipids identified in Peaks I, II and III isolated from oxidized PAPC. They possessed identical functional groups and differed only by the chain length of the truncated fatty acid tethered to the sn-2 position (Fig. 1c) . The core structural motif conserved amongst the various isolated oxidized PC species that support CD36-binding activity is shown in Fig.   1d . Peak II isolated from NO 2 -PAPC and NO 2 -PLPC vesicles represented the major overall fraction with CD36 binding activity observed during initial HPLC separation (Fig. 1a, 1b) . The biologically (Fig. 4c) . The nature of lipids that were used as carriers for oxPC CD36 did not appear to be critical for demonstrating CD36-specific recognition since comparable results were observed using various lipid carriers, including PAPC, PLPC (Fig. 4c) HOdiA-PC; Fig. 4c ), and those possessing γ oxo (carbonyl) vs. hydroxyl moieties also had highest affinity for CD36 (Fig. 4c) . Fig. 5a ). This suggests that the binding site for oxPC species (and oxLDL) on CD36 is spatially and functionally distinct from that of either PS, thrombospondin-1 or long chain fatty acids. Consistent with this hypothesis, these ligands (i.e.
thrombospondin-1, PS, free fatty acids) failed to block CD36-dependent recognition of PAPC vesicles containing oxPC CD36 species (Fig. 5b , data for KOOA-PC shown).
To further explore structural features responsible for supporting CD36 binding activity in oxidized lipids, multiple synthetic PC species with distinct oxidized fatty acids at their sn-2 position (e.g. various hydroperoxides, hydroxides or the indicated structural analogs) were synthesized and examined -all failed to serve as CD36 ligands (Table 1) . Significantly, OV-PC was considerably less effective in binding to CD36 than oxPC species possessing sn-2 esterified γ-hydroxy(oxo)-α,β-unsaturated carbonyl-containing fatty acids ( Table 1) . None of the oxidized free fatty acids examined bound to CD36 (whether free or incorporated (5-50 mol%) in small unilamellar vesicles comprised of PAPC). Moreover, either repositioning of the γ-hydroxy moiety by one methylene group to the δ-position (HOT-PC, (45, (47) (48) (49) (50) . While studies thus far reported have shown that ligands on oxLDL for CD36 are contained within the lipid portion of the particle (10,11,51-53), the structural nature of the lipids that support CD36 binding has not been elucidated.
Identification of the lipid ligand(s) has been difficult owing to the large number and functional
complexity of products generated during oxidation of LDL and the daunting challenges of their isolation, structural and biochemical characterization and synthesis.
We now report the first systematic study aimed at identifying the structures of specific oxidized lipids that serve as ligands for the scavenger receptor CD36. The structures of the specific molecular species of choline glycerophospholipids identified were established using a combination of cell binding studies and multiple distinct chromatographic and mass spectrometric methods, in conjunction with: i) results of numerous derivatization strategies to ascertain functional groups on isolated products; ii) inference of structures of products that appeared plausible based upon known mechanisms of lipid oxidation and fragmentation; and iii) de novo synthesis of each lipid. (Fig. 7) . Despite the vast array of products formed following oxidation of even a single molecular species of precursor PC (i.e. PAPC or PLPC), only a small number manifest significant CD36 binding activity.
The structural motifs in oxPC species that support CD36 binding are highly conserved (Figs.   1d) . The α,β unsaturated group generates a bi-planar core about which a trans configuration of polar oxygen atoms must be displayed (OH or C=O at γ-position, C=O or (C=O)OH at sn-2 fatty acid terminus). Binding is relatively independent of the long chain fatty acid bound at the sn-1 position (palmitate vs. oleate; data not shown). Incorporation of all of these elements in an amphipathic molecule such as PC was required since neither the free oxidized fatty acids nor their cholesterol ester analogs were recognized by CD36 (Table 1) Finally, as noted above, only minimal alterations in structure to the core conserved structural motif that supports CD36 binding results in complete loss of CD36 binding activity ( (46) . Following more extensive oxidation of LDL, protein modification may become significant, including formation of protein-lipid adducts that could participate in CD36 recognition (11) .
For instance, BSA extensively modified by OV-PC competes for the binding of oxLDL to CD36 and is recognized by a monoclonal antibody to oxidized PAPC (EO6) that inhibits binding of oxLDL to CD36 (11) . Recent characterization of EO6 suggests that it recognizes epitopes similar to the Schiff base adduct formed between OV-PC and lysine residues, as well as the aldol condensation product of OV-PC, but not monomeric lipid (55) . In the current study we found that free OV-PC was a poor ligand for CD36 (Table 1) . We did not directly assess whether a complex formed between BSA and OV-PC might serve as a ligand, although OV-PC incubated for 3h in culture medium containing 10% LPDS failed to inhibit CD36-mediated binding of oxLDL.
The formation of α,β-unsaturated γ-hydroxy aldehydes, such as 4-HNE, as truncated fatty acid products generated during transition metal ion-catalyzed oxidation reactions is well documented (39, 56, 57) . Recent studies examining products formed during oxidation of free polyunsaturated fatty acids demonstrated that HOOA (5-hydroxy-8-oxo-6-octenoic acid) and HODA (9-hydroxy-12-oxo-10 dodecenoic acid) are co-produced in yields similar to 4-HNE during free radical oxidation of arachidonic and linoleic acids, respectively (38,58). Based upon this observation, it was postulated that by analogy to the formation of 4-HNE, HOOA-PC and HODA-PC might be formed during free radical oxidation of PAPC and PLPC, respectively (59) . Antibodies raised against proteins modified by sn-2 α,β-unsaturated, γ-hydroxy-carbonyl-containing PCs were generated and used to demonstrate the presence of similar epitopes within LDL oxidized in vitro and in plasma proteins recovered from individuals with atherosclerosis (59) . The present studies directly demonstrate that HOOA-PC and HODA-PC are formed within LDL exposed to multiple distinct oxidation pathways (Fig. 6 ). The present studies also significantly extend the number of species identified within this family and establish these unique oxPC species as ligands for the scavenger receptor CD36. Finally, while some of the oxPC CD36 species identified likely share chemical reactivities similar to 4-HNE (e.g. HOOA-PC and HODA-PC), such as the ability to generate Schiff bases and Michael adducts, this property is not critical to CD36
recognition. Binding studies performed in the presence vs. absence of LPDS or BSA yielded comparable results. Moreover, the specific oxPC CD36 species that serve as the more potent CD36 ligands are relatively unreactive chemically (i.e. the hydroxy acids HOdiA-PC and HDdiA-PC, and the keto acids KDdiA-PC and KOdiA-PC). Taken together, the present studies suggest that a high affinity, reversible interaction serves as the recognition event between CD36 and oxPC CD36 species.
They also exclude a significant role for irreversible covalent modification of nucleophilic residues on CD36 by oxPC CD36 species.
One of the methodological challenges of the present study was the ease with which many of the oxPC CD36 species were further oxidized during sample handling, even while using methods aimed at excluding redox-active transition metal ions and inclusion of free radical scavengers such as BHT at all stages of analysis. For example, exposure of trace levels of synthetic oxPC CD36 species to conventional isolation procedures reported for analysis of other known oxPAPC species found in vivo (e.g. OV-PC, G-PC), resulted in substantial conversion of the oxPC CD36 species into more advanced (and truncated) oxidation products including OV-PC and G-PC. Similarly, we observed that oxPC CD36 derived from PLPC readily generated ON-PC and ND-PC, the structural analogs of OV-PC and G-PC. Our finding that OV-PC, G-PC, ON-PC and ND-PC are readily generated from certain α,β-unsaturated, γ-hydroxy(oxo)carbonyl-containing PC indicates these more truncated phospholipids may be remnants of some oxPC CD36 species. LC/ESI/MS/MS analyses of various oxPC species were performed using conditions developed to minimize intrapreparative oxidation of lipids and preserve near quantitative recovery of each analyte monitored (based upon control studies using trace levels of individual synthetic standards). When analyzed using these methods, the contents of oxPC CD36 species observed were comparable to that detected for the more terminally oxidized end products of PAPC, OV-PC and G-PC (Fig. 6a) . It remains to be determined whether the oxPC CD36 species identified possess biological activities extending beyond serving as ligands for CD36.
The present studies suggest several potential strategies for blocking foam cell formation in vivo.
These include preventing formation of oxPC CD36 through use of antioxidant strategies or enzyme (i.e.
MPO) inhibitors, as well as development of selective receptor antagonists (i.e. to the CD36 "oxLDL binding site"). CD36 is a multiligand receptor with functionally distinct binding domains for its ligands (60) (61) (62) (63) . The competition studies presented in Fig. 5 suggest the feasibility of developing CD36 receptor antagonists that specifically block recognition of oxPC CD36 species at the CD36 binding site for oxLDL without significant impact on CD36-dependent recognition of ligands such as fatty acids, thrombospondin-1 and PS. The structural insights into the molecular patterns recognized by the "oxLDL" site of CD36 identified herein may provide a platform for the rational development of such potential therapeutic inhibitory agents.
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